Tetrahydrocannabiorcol

Tetrahydrocannabiorcol (THCC) is a C1-alkyl analog of delta-9-tetrahydrocannabinol (THC), where the pentyl side chain is replaced by a methyl group. It is produced by Xinteza using a proprietary biosynthesis platform that utilizes engineered microorganisms to generate high-purity cannabinoids. Unlike the more common C5-analog THC, THCC is reported to have significantly lower affinity for the cannabinoid receptors (CB1 and CB2) and lacks the potent psychoactive effects associated with THC. Xinteza markets THCC as a specialized active pharmaceutical ingredient (API) for research into the therapeutic potential of minor cannabinoids and their interactions with the endocannabinoid system.

Other names

THCCTetrahydrocannabinol-C1Tetrahydrocannabinol-C-1Tetrahydrocannabinol-C 1Delta-9-tetrahydrocannabiorcolDelta9-tetrahydrocannabiorcolDelta 9-tetrahydrocannabiorcol